BUY
|
Original-Research: Cantourage Group SE - from NuWays AG
Classification of NuWays AG to Cantourage Group SE
Full steam ahead, FY24 guidance raised; PT up Topic: Cantourage raised its FY24e guidance following continued sequential growth throughout Q4 with November sales reaching € 7.2m, exceeding the previously strongest quarter by 31%. Cantourage announced a particularly strong November sales figure of € 7.2m, a 31% increase compared to October (previous annual high). With this, Jan. to Nov. sales stand at € 42.9m, a roughly 80% increase compared to the full year 2023 figure. The driver behind this strong growth is the reclassification of medical cannabis (no longer qualified as a narcotic) in Germany, which took effect at the end of April and hence made obtaining a prescription notably easier. This is also visible in the estimated number of cannabis patients, which is seen to have doubled to 0.5-0.6m. Further, Cantourage is also experiencing a sharp increase in demand at its treatment facility in UK. Taking into account continued strong demand throughout the remainder of the year as stated in yesterday’s press release, the company should be on track to reach Q4 sales of some € 19m (eNuW), a significant acceleration compared to before the legislative changes (Q1 sales of € 6.2m). The strong sales development is seen to increasingly feed down to the bottom line with a Q4 EBITDA margin expectation of 8.1% (eNuW) compared to a slightly negative figure last year. More importantly, we also expect Cantourage to begin generating positive free cash flows. For FY24e, the company is seen to report € 1.5m, a notable improvement compared to FY23’s € -3.1m. As a result of the strong operational ytd. performance management increased its FY24e guidance, now expecting € 46-50m sales (eNuW € 49.2m) and € 3-4m EBITDA (eNuW € 3.6m); old guidance: at least € 40m sales and € 2m EBITDA. While EBIT should still be slightly negative, it is important to note that is only due to the planned amortization of the operating GmbH value that was transferred into the SE as part of the listing in 2022. Business to further scale during FY25e and beyond. Thanks to unbroken demand on the back of growing patient numbers and further de-bottlenecking at its processing sites, Cantourage should be well positioned to remain at the forefront of the dynamic market, reflected by our sales growth estimates. BUY with a new € 11.50 PT (old: € 10.00) based on DCF. You can download the research here: http://www.more-ir.de/d/31501.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2045487 06.12.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.